Xenon Feels No Pain After $41M Upfront From Teva
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.
Teva and Xenon collaborate to develop the Canadian company’s lead pain product; the deal could net Xenon as much as $376 million and will fit snugly into the Israeli company’s new focus.